High-Sensitivity C-Reactive Protein Combined with Low-Density Lipoprotein Cholesterol as the Targets of Statin Therapy in Patients with Acute Coronary Syndrome

International Heart Journal
Ming FangXinming Li

Abstract

To investigate the combination of high-sensitivity C-reactive protein (hs-CRP) and Low-density lipoprotein (LDL)-C as the targets for statin treatment in patients with acute coronary syndrome (ACS). This single-center, prospective, randomized study was performed in 400 patients treated with atorvastatin 40 mg/day for 1 month and then with atorvastatin 20 mg/day as maintenance. The patients were randomized to the LDL group (LDL-C target of < 2.07 mmol/L according to the Chinese dyslipidemia guidelines) and to the LDL-CRP group (LDL-C target of < 2.07 mmol/L and hs-CRP target of < 3 mg/L). The patients were followed up for major adverse cardiac events (MACE) at 6, 12, and 18 months. The two groups had similar baseline characteristics and 391 patients completed the follow-up. No differences were found in LDL-C between the two groups, but a difference was found in hs-CRP at 12 and 18 months. There was a significant difference in revascularization (8.7% versus 3.6%, P = 0.04) and MACE (16.8% versus 9.7%; P = 0.04) between the LDL and LDL-CRP groups at 18 months. Compared to LDL-C as the single target, targeting both LDL-C and hs-CRP by statin therapy in patients with ACS could further reduce the incidence of MACE and the residual ca...Continue Reading

References

Jul 4, 2001·JAMA : the Journal of the American Medical Association·M A AlbertUNKNOWN PRINCE Investigators
Mar 10, 2004·The New England Journal of Medicine·Christopher P CannonUNKNOWN Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators
Jul 9, 2004·Coronary Artery Disease·Jean Davignon
Nov 9, 2004·Atherosclerosis. Supplements·T R PedersenUNKNOWN Scandinavian Simvastatin Survival Study Group
Jan 7, 2005·The New England Journal of Medicine·Paul M RidkerUNKNOWN Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Inv
Nov 17, 2005·JAMA : the Journal of the American Medical Association·Terje R PedersenUNKNOWN Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group
Nov 27, 2007·Circulation Journal : Official Journal of the Japanese Circulation Society·Takashi YamadaUNKNOWN REACH Study Group
Oct 1, 2008·Journal of Internal Medicine·J P CasasM B Pepys
Nov 11, 2008·The New England Journal of Medicine·Paul M RidkerUNKNOWN JUPITER Study Group
Mar 24, 2009·Annual Review of Immunology·Elena Galkina, Klaus Ley
Nov 28, 2009·Journal of the American College of Cardiology·Peter LibbyUNKNOWN Leducq Transatlantic Network on Atherothrombosis
Jun 18, 2010·Coronary Artery Disease·Daniel S Menees, Eric R Bates
Nov 2, 2011·Seminars in Thoracic and Cardiovascular Surgery·Jennifer S Lawton
Nov 8, 2011·British Journal of Clinical Pharmacology·Jean Davignon
Oct 5, 2012·The New England Journal of Medicine·UNKNOWN Emerging Risk Factors CollaborationJohn Danesh
Dec 15, 2012·Circulation·Alan S GoUNKNOWN American Heart Association Statistics Committee and Stroke Statistics Subcommittee
Jul 20, 2014·Current Atherosclerosis Reports·Enrica GoliaPaolo Calabrò
Mar 15, 2016·International Heart Journal·Takeshi Soeki, Masataka Sata

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.